Form 4: Werewolf Therapeutics Director Acquires Stock Options

Meeta Chatterjee, a director of Werewolf Therapeutics, Inc., was granted stock options to purchase 17,500 shares of common stock at an exercise price of $4.88 on May 24, 2024.

Summary

• On May 24, 2024, Meeta Chatterjee, a director of Werewolf Therapeutics, Inc. (HOWL), was granted stock options.
• The stock options allow Chatterjee to purchase 17,500 shares of the company's common stock.
• The exercise price for these options is $4.88 per share.
• The options vest in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the grant date, contingent upon continued service as a director.
• The options expire on May 23, 2034.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The granting of stock options is a common practice and doesn't inherently indicate positive or negative sentiment.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as directors and officers. This allows investors to monitor insider sentiment and potential alignment with company performance.

Stakeholder Impact

• The granting of stock options to a director can align their interests with those of shareholders, potentially leading to increased shareholder value.

Key Dates